Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biobased Chemicals

JCG will build Chugai Pharmaceutical’s API plant

by Rick Mullin
August 19, 2023 | A version of this story appeared in Volume 101, Issue 27

JGC Holdings, an engineering company headquartered in Yokohama, Japan, has been awarded a contract by Chugai Pharmaceutical to build an active pharmaceutical ingredient (API) manufacturing plant for clinical- and early-stage commercial biologic drugs. The plant, to be constructed at Chugai’s facility in Utsunomiya, Tochigi Prefecture, will include continuous production functions as well as batch manufacturing. The facility is scheduled for completion in 2026.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.